Q Biomed Stock Price, News & Analysis

Q BioMed Inc. (OTCQB: QBIO) is a cutting-edge biomedical acceleration and development company based in New York, New York. Established in 2013 and formerly known as ISMO Tech Solutions, Inc., Q BioMed has positioned itself as a vital player in the life sciences and healthcare sectors.

The company's principal focus is on licensing, acquiring, and providing resources to various healthcare and life sciences enterprises. Among its core products is Strontium Chloride Sr89, a radiopharmaceutical therapeutic designed to alleviate bone cancer pain. Additionally, Metastron, another radiopharmaceutical, offers therapeutic solutions for metastatic cancer bone pain. Q BioMed is also pioneering several other significant projects, including MAN-01, a pre-clinical candidate targeting primary open-angle glaucoma; QBM-001, aimed at treating rare pediatric non-verbal autism spectrum disorder; and Uttroside-B, developed for liver cancer treatment.

A noteworthy partnership with Mannin Research underscores Q BioMed's commitment to innovation, collaborating on the development of novel treatments for COVID-19. The company’s strategy emphasizes not only acquiring undervalued biomedical assets but also providing these assets with the critical resources, developmental support, and capital necessary for reaching their full potential.

Q BioMed is currently navigating some financial challenges. According to a recent update, the company was unable to file complete audited financials for 2022 due to capital constraints and the costs involved in the audit process. This led to a downgrade to the 'Expert Market' segment of the OTC. Despite these challenges, Q BioMed is actively engaging with consultants and bankers to restructure its funding and potentially relist on the market or pursue mergers and acquisitions with compatible entities.

Q BioMed remains steadfast in its mission to unlock shareholder value and continues to explore various options for financial restructuring. The company is dedicated to providing regular updates to its shareholders and ensuring transparency throughout this process.